Home / Auditor changes / Avidity Biosciences, Inc.
Filed 2025-04-29 路 Form 8-K 路 Accession 0001599901-25-000091 micro
Price before filing: n/a (n/a close, split/dividend-adjusted)
Market cap at flag: n/a 路 Latest: $131.2M (2026-10-16)
| Window | RNA | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | n/a | n/a | n/a | |
| 90 days | n/a | n/a | n/a | |
| 180 days | n/a | n/a | n/a |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 6 insiders sold $3.3M (10 sales)
30 days after: 1 insider sold $190K (1 sale)
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2025-02-03 | Gallagher Kathleen P. Chief Program Officer | Sale | 5,875 | $32.16 | $189K | yes | Form 4 |
| 2025-03-03 | Gallagher Kathleen P. Chief Program Officer | Sale | 5,875 | $29.41 | $173K | yes | Form 4 |
| 2025-03-11 | Flanagan W. Michael Chief Scientific Officer | Sale | 20,000 | $30.13 | $603K | yes | Form 4 |
| 2025-03-20 | Boyce Sarah President and CEO, Director | Sale | 31,540 | $31.06 | $980K | yes | Form 4 |
| 2025-03-20 | Flanagan W. Michael Chief Scientific Officer | Sale | 11,780 | $31.06 | $366K | yes | Form 4 |
| 2025-03-20 | Hughes Steven George Chief Medical Officer | Sale | 9,578 | $31.06 | $297K | yes | Form 4 |
| 2025-03-20 | MacLean Michael F Chief Financial Officer | Sale | 7,935 | $31.06 | $246K | yes | Form 4 |
| 2025-03-20 | McCarthy Teresa Chief Human Resources Officer | Sale | 7,778 | $31.06 | $242K | yes | Form 4 |
| 2025-04-01 | Gallagher Kathleen P. Chief Program Officer | Sale | 5,546 | $27.83 | $154K | yes | Form 4 |
| 2025-04-01 | Gallagher Kathleen P. Chief Program Officer | Sale | 329 | $27.83 | $9K | yes | Form 4 |
| 2025-04-29: red flag filed | |||||||
| 2025-05-01 | Gallagher Kathleen P. Chief Program Officer | Sale | 5,875 | $32.40 | $190K | yes | Form 4 |
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-01-29 to 2025-05-29. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"As a result of this process, on April 25, 2025, the Audit Committee approved the appointment of Deloitte & Touche LLP ("Deloitte") as the Company's independent registered public accounting firm for the year ending December 31, 2025, with such appointment to be effective immediately following the filing of the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2025 (the "Q1 Form 10-Q")."
Quoted from the filing. Source
The company changed its outside auditor (8-K Item 4.01). A dismissal or resignation, especially near an annual report or with reported disagreements, is a warning sign. Changes caused by audit firms merging are usually routine.
Type: dismissed
Disagreements reported: no
Former auditor: BDO USA, P.C. · New auditor: Deloitte & Touche LLP
Read the original filing on SEC.gov →
🔔 Get email alerts for this company
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.